Marketing for research tools, instruments, lab software, CROs and CDMOs. Your buyers have PhDs and procurement logins, and they check claims against the literature.
A senior team that does the homework, pay as you go, no lock-in. Your first call is with a co-founder.
42% of scientific purchases close within a month and 64% involve one to three people (AZoNetwork, 2026). Capital instruments and CRO qualification take quarters. One playbook can't serve both.
Search engines influence 87% of scientific purchases and manufacturer websites 88%, while AI-assisted product comparison rose 68% in a year (AZoNetwork, 2026). Sales reps are a declining channel.
A product named in the methods section carries more weight than any ad, and regions led by a trial's lead investigator adopt 36% more (Agha and Molitor, NBER). Named scientific authority moves markets.
NIH grant obligations ran 42 to 44 days behind their usual pace into 2026, and academic demand stayed weak while pharma budgets recovered. The end market sets your calendar.
Method-level content drafted with your scientists and sourced like a paper: application notes, troubleshooting guides, technique explainers. It answers the questions your buyers arrive with, and it is the format AI search engines cite when they answer for you.
Spec-complete product pages built against method, application and comparison searches. With search influencing 87% of scientific purchases and AI comparison up 68% in a year, the demand-capture layer is your documentation, so we treat it as campaign material.
Trade shows are the largest marketing cost line in life sciences, so we make the spend compound: pre-booked meetings against a named-account list, side events, and follow-through that turns SLAS, ACHEMA or BIO scans into evaluations.
Where a distributor owns your DACH or APAC revenue, we arm the channel: co-branded campaigns, product data and claims they can reuse, and demand programs that make your catalog the easiest one in their bag to sell.
Therapeutic-area positioning, since expertise is the top selection criterion for small sponsors, plus RFI and bid-defense materials and audit-ready documentation. The goal is being credible at the exact moment a consultant or peer builds the shortlist.
If it wouldn't survive the methods section, it doesn't go in the campaign.
We don’t like to work from templates. Your Head of Growth builds the strategy around your products, your buyers and how labs evaluate suppliers. The cards below show one example for a health tech company.
Research tools, instruments, reagents, lab software, CROs and CDMOs, sold to scientists, lab managers and procurement. Proof bar: citations, protocols, batch consistency.
Platforms and therapeutics developers selling science to pharma R&D and investors. Proof bar: peer-reviewed publication. Client: Cradle.
Devices and diagnostics hardware sold through procurement and value analysis committees. Proof bar: clinical data plus a per-procedure economic case.
We interviewed six practitioners for this report: the co-founder and CEO of a hospital AI company who spent a decade at Philips, the Head of AI at a company that predicts migraines from wearable data, and four of our own Heads of Growth and co-founders. We then checked what they said against OECD, WHO and European Commission data and peer-reviewed research. It was written for health tech, and most of what it says about evidence, buying committees and channels applies to anyone selling to scientists.
Amsterdam and New York, serving life science companies across Europe and the US, with Boston, the Bay Area, Basel and Cambridge as target hubs.